sodium tetradecyl sulfate

Drug Overview

In the clinical field of hematology and vascular medicine, managing venous disorders is essential for preventing complications like deep vein thrombosis and chronic skin changes. Sodium tetradecyl sulfate (STS) is a potent medication belonging to the Sclerosing Agent drug class. It is widely recognized as the gold standard for the non-surgical treatment of diseased veins.

STS is a synthetic, anionic surfactant (a surface-active agent) that acts as a detergent on the inner lining of blood vessels. By inducing a controlled injury to the vein, it facilitates the permanent closure of dysfunctional vessels. This procedure, known as sclerotherapy, is a minimally invasive alternative to traditional surgical stripping.

• Generic Name: Sodium tetradecyl sulfate
• US Brand Names: Sotradecol
• International Brand Names: Fibro-Vein, Trombovar
• Route of Administration: Intravenous (specifically via slow intraluminal injection into the varicose vein)
• FDA Approval Status: FDA-approved for the treatment of small, uncomplicated varicose veins of the lower extremities.

What Is It and How Does It Work? (Mechanism of Action)

When injected into a varicose vein, the drug acts as a Targeted Therapy for the vascular endothelium (the inner layer of cells). Its action can be broken down into three hematological phases:

1. Endothelial Denudation: At the molecular level, the detergent molecules of STS dissolve the lipids (fats) within the cell membranes of the endothelial cells. This causes the cells to shed away from the vein wall, exposing the underlying subendothelial tissue.
2. Activation of the Coagulation Cascade: Once the subendothelial layer is exposed, the body’s natural clotting mechanism is triggered. Platelets adhere to the damaged site, and the intrinsic coagulation cascade is activated. Unlike systemic clotting, this is a localized, controlled process.
3. Fibrosis and Obliteration: The interaction between the drug and the vein wall causes the vein to collapse. A firm, localized thrombus (clot) forms, which is eventually replaced by a fibrous cord of connective tissue. Because the vein is now solid and closed, blood is naturally rerouted to healthier, functioning veins.

This mechanism provides an effective solution for venous insufficiency without the systemic hemorrhage risk reduction protocols required by anticoagulants, as the drug’s effect is neutralized quickly by blood proteins once it enters larger circulation.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for sodium tetradecyl sulfate is the treatment of small, uncomplicated varicose veins in the legs. This includes telangiectasias (spider veins), reticular veins (small blue-green veins), and smaller tributaries of the saphenous system. In the context of hematology and vascular health, it is used to alleviate symptoms such as aching, swelling, and heaviness caused by venous reflux.

Other Approved & Off-Label Uses

While its primary focus is lower extremity veins, STS is utilized across various medical specialties:

• Venous Malformations: Used in the management of congenital vascular clusters in both pediatric and adult patients.
• Hemangiomas: Targeted treatment of benign blood vessel tumors.
• Hydroceles and Cysts: Occasionally used off-label as a sclerosant to close the sac around a hydrocele or certain types of cysts.
• Esophageal Varices: Although less common than other agents, it has been used in the past to treat bleeding veins in the esophagus of patients with liver disease.

Dosage and Administration Protocols

The concentration and volume of STS are strictly determined by the size and diameter of the vein being treated. It is often prepared as a “foam” by mixing the liquid drug with air or physiological gas, which increases its surface area and efficacy in larger vessels.

Important Adjustments:

• Maximum Dose: Total dose should generally not exceed 10 mL of a 3% solution per treatment session to minimize systemic toxicity.
• Foam Administration: When used as a foam, the volume of gas must be carefully monitored. International guidelines often suggest a maximum of 10 mL of foam per session.
• Extravasation Prevention: STS must stay inside the vein. If the drug leaks into the surrounding skin (extravasation), it can cause severe tissue necrosis (skin death).

Clinical Efficacy and Research Results

Clinical study data from the period of 2020-2026 has reaffirmed the high efficacy of STS, particularly when used in ultrasound-guided foam sclerotherapy (UGFS). Research published in major vascular journals indicates that for reticular and small varicose veins, STS achieves an initial occlusion rate of approximately 85% to 92%.

Numerical data from recent trials comparing STS to other sclerosants, like polidocanol, suggest that STS may have a higher “potency per milliliter,” making it highly effective for larger, more stubborn vessels. Long-term follow-up studies (2024) show that patient satisfaction scores remain high due to the lack of surgical scars and the rapid return to daily activities. In patients with chronic venous leg ulcers, the use of STS to close the underlying “feeder” veins has been shown to accelerate ulcer healing by nearly 40% compared to compression therapy alone.

Safety Profile and Side Effects

Black Box Warning

Sodium tetradecyl sulfate does not currently carry an FDA Black Box Warning. However, it is classified as a high-alert medication due to the risk of severe tissue damage if injected outside of the vein.

Common side effects (>10%)

• Hyperpigmentation: Brown staining of the skin along the treated vein (usually fades over 6–24 months).
• Injection Site Pain: A transient burning or stinging sensation during administration.
• Neovascularization: The appearance of tiny new red vessels near the treated site (also known as “matting”).

Serious adverse events

• VTE/Thrombosis Risk: While the goal is a local clot, there is a small risk of deep vein thrombosis (DVT) or pulmonary embolism if the drug enters the deep venous system.
• Tissue Necrosis: Severe skin ulcers caused by the drug leaking out of the vein.
• Hypersensitivity: Anaphylaxis (severe allergic reaction) is rare but can occur; emergency equipment must always be present.
• Stroke/Neurological Events: Very rare reports of transient visual disturbances or stroke, primarily associated with foam sclerotherapy in patients with a “hole in the heart” (patent foramen ovale).

Management Strategies

Post-procedure management is key to safety. If hyperpigmentation occurs, avoiding sun exposure is recommended. To manage DVT risks, patients are instructed to walk immediately after the procedure. If extravasation occurs, the area is often infiltrated with saline or hyaluronidase to dilute the drug and prevent skin loss.

Research Areas

Current research in 2026 is focusing on “Automated Foam Production Systems,” which aim to standardize the bubble size in STS foam to make the drug even more predictable. There are also active clinical trials investigating the use of STS in treating pelvic congestion syndrome, a condition where varicose veins develop around the ovaries and uterus in women. Additionally, researchers are looking at the potential of STS in the field of interventional oncology to “starve” certain tumors by sclerosing the blood vessels that supply them.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Duplex Ultrasound: Essential to map the venous anatomy and check for existing deep vein clots.
• CBC (Complete Blood Count): To check baseline platelet levels.
• Coagulation Profile (PT/INR/aPTT): To ensure the patient does not have an undiagnosed hypercoagulable state or bleeding disorder.

Precautions during treatment

• Compression Therapy: Patients must be prepared to wear medical-grade compression stockings (usually 20-30 mmHg) immediately after treatment for 1 to 3 weeks to keep the vein walls pressed together.
• Vigilance for Thromboembolism: Patients should be monitored for sudden leg swelling, chest pain, or shortness of breath for two weeks post-procedure.

“Do’s and Don’ts” List

• DO walk for at least 30 minutes immediately following the injection to encourage deep vein circulation.
• DO notify your doctor if you experience extreme pain or a darkening ulcer at the injection site.
• DO stay hydrated before and after the procedure.
• DON’T take a hot bath, sit in a sauna, or engage in high-impact aerobic exercise for the first 48 to 72 hours.
• DON’T apply tanning lotions or expose the treated legs to direct sunlight for at least 4 weeks.
• DON’T remain sedentary (sitting or standing still) for long periods in the days following treatment.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Sodium tetradecyl sulfate is a powerful chemical agent that must be administered only by trained vascular or hematology specialists. Always discuss the risks and benefits of sclerotherapy with your physician before undergoing the procedure.